Therapeutic options for patients with pretreated advanced high-grade glioma (HGG) are limited. Sorafenib, a small molecule with multiple potential beneficial actions, appears particularly promising. We reviewed the outcomes of 30 patients with recurrent or progressive HGG treated with sorafenib within a named patient program. Overall, 16 patients suffered from recurrent or progressive glioblastoma multiforme and 14 patients had grade 3 gliomas. All but four patients had previously undergone surgical debulking; all but one patient had received previous standard multimodal treatment; and 18 patients (60%) had received more than one line of chemotherapy, in median three. Progression-free survival (PFS), defined as the time from initiation of sorafenib to treatment discontinuation because of tumor progression or death, was selected as the endpoint. The use of sorafenib resulted in a median PFS of 3 months [95% confidence interval (CI) 1.9-4.1 months] in patients with glioblastoma and of 3.1 months (95% CI 1.4-4.8 months) in patients with other HGG. The PFS-6 for the whole cohort was 23%. Sixteen patients reported adverse events, mostly moderate, with hypertension as the most frequently reported toxicity (seven patients). One patient died of cerebral bleeding (grade 5 toxicity). The overall survival after initiation of sorafenib was 6 months (95% CI 3.9-8.0 months) for patients with glioblastoma multiforme and 10 months (95% CI 3.1-16.9 months) for patients with HGG. In this retrospective analysis of heavily pretreated patients with HGG, sorafenib monotherapy was associated with tumor stabilization in a small subset of patients. The riskbenefit ratio was acceptable in the context of an apparent clinical benefit in patients with a fatal disease. Anti-Cancer Drugs 25:723-728 c 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
Gliomas account for B35% of all primary brain tumors in Austria [1] . The most common type is glioblastoma, accounting for 56% of all gliomas, followed by diffuse astrocytomas (10%) and oligodendroglial tumors (9.7%) [1] . The latest published incidence rates in Austria are 5.33/100000 people per year for astrocytic tumors and 0.7/100000 people per year for oligodendroglial tumors [1] .
Although standard therapies can prolong the duration of survival, the median survival time for patients with recurrent glioblastoma is usually very limited. To date, there is no established standard of care for patients with recurrent high-grade glioma (HGG). Salvage treatment remains palliative, and therefore should meet the palliative needs. A variety of therapies have been investigated in this setting, and to date no breakthrough has been achieved. Second surgery or second courses of irradiation or chemotherapy have been used, trying to meet the affected patient's needs individually. With growing knowledge about the underlying biological mechanisms of glioma oncogenesis, targeted therapies were introduced and investigated in patients with glioma recurrence [2, 3] . Bevacizumab is one of these new therapeutic strategies. In 2009, it was approved for the treatment of recurrent glioblastoma by the US Food and Drug Administration and Swissmedic but not by the European Medicines Agency.
Sorafenib, a small molecule with multiple potential targets, appears particularly promising for treatment in patients with recurrent gliomas [4] . Overexpression of platelet-derived growth factor receptor-a, a receptor tyrosine kinase, has been demonstrated in all grades of astrocytoma, indicating a potential role in tumor development. Platelet-derived growth factor receptor is one of the targets of sorafenib. Angiogenesis is another crucial step in the progression of gliomas. One of the key factors is vascular endothelial growth factor, also a target of the multikinase inhibitor sorafenib. Further targets are kinases RAF-1 and B-RAF, the Fms-like tyrosine kinase 3, and the c-KIT protein (c-KIT) [5] . Sorafenib has also been shown to inhibit the Janus-activated kinase/signal transducers and activators of transcription 3 signaling, identified as important for growth arrest and induction of apoptosis in glioblastoma cells [6] . In human glioblastoma cell lines, primary cultures, and mice xenografts, sorafenib inhibited cell proliferation and induced apoptosis. The combination with rottlerin, a protein kinase C inhibitor, produced marked potentiation of growth inhibition in human malignant glioma cells [7] . Recently, it has been shown that vitamin K1 also enhances the cytotoxic effect of sorafenib in glioma cells [8] .
However, there is not only a preclinical rationale for the use of sorafenib. A phase-I clinical trial determined the toxicity profile, the maximum tolerated dose (MTD), and pharmacokinetics in patients with recurrent or progressive malignant glioma, and showed that sorafenib should be considered for further evaluation, given the ease of oral administration, tolerable side effect profile, and favorable pharmacokinetics [9] . There are only limited data on sorafenib in this setting of heavily pretreated patients with disease recurrence. This report is intended to add information from a practical point of view concerning the use of sorafenib within a named patient program (NPP). The objective of this analysis was to assist treatment decision in heavily pretreated patients with HGGs by assessing the efficacy and toxicity of sorafenib, while keeping in mind the limitations of a retrospective analysis.
Methods
Following approval by the Ethics Committee, we reviewed the patient's records from Clinical Division of Oncology at the Department for Internal Medicine I of Medical University of Vienna to identify patients with recurrent or progressive HGGs who participated in the NPP with sorafenib. The program initiated by Bayer Austria has been open for participation since 2006, granting access to drug for cancer patients who have exhausted all alternative treatment options and who did not meet the clinical trial entry criteria, but were still in an adequate performance status. We identified 30 patients with recurrent or progressive HGGs treated with sorafenib within the NPP.
Data extracted from the records included (but were not limited to) sex, birth date, date of initial diagnosis, histology, number and type of surgeries, use of radiation therapy, lines and duration on prior chemotherapies, dates of sorafenib initiation and discontinuation, reason for stopping treatment, best response to sorafenib, and drugrelated adverse events. Diagnoses refer to the histologic diagnoses made at the last surgery or biopsy. The analyses are based on the data cutoff point of 30 June 2012.
Patients underwent gadolinium-enhanced MRI scans every 3 months or at shorter intervals when clinical signs of progression were seen. Complete blood count with differential count and a serum biochemistry profile were performed during each follow-up visit scheduled every other week. Sorafenib was administered orally to all patients at a dose of 400 mg twice daily continuously (2-0-2), after a dose escalation phase of 10 days. For the first 3 days, patients received only one dose of 200 mg sorafenib (1-0-0). Thereafter, they received a dose of 200 mg twice daily from day 4 (1-0-1). On day 7, the dose was increased to 400 mg in the morning and 200 mg in the evening (2-0-1).
Patients continued sorafenib until evidence of disease progression, nonmanageable adverse events, or death. The outcomes of treatment patterns included date and reasons for treatment discontinuation. Time-to-progression, defined as the time from initiation of sorafenib to treatment discontinuation because of tumor progression or death, was selected as the endpoint. In case of loss to follow-up, the last visit was chosen as the end date. For four patients continuing sorafenib therapy, the last day of June 2012 was taken as the data cutoff point. The best response was evaluated following the RANO criteria [10] .
The safety outcomes included the numbers and proportions of patients who experienced specific adverse events of grade 2 or higher. The study investigators assessed and documented toxic events and assigned grade levels using the Common Terminology Criteria for Adverse Events, version 3.0 and later 4.0.
Because of the small number of patients included, no formal statistical analysis was performed. Descriptive statistics were used to describe patient's baseline characteristics, treatment patterns, and adverse events. Medians and ranges were used to describe continuous variables, and frequencies and percentages were used for categorical ones (qualitative data). Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method.
Results

Patient characteristics
Thirty patients with recurrent or progressive HGGs were treated with sorafenib from January 2007 to June 2012. The patient characteristics are detailed in Table 1 . There were 20 men and 10 women, with a median age of 46 years. Sixteen patients suffered from recurrent or progressive glioblastoma multiforme (GBM) and 1 4 patients had grade 3 gliomas (anaplastic astrocytoma in nine patients, anaplastic oligoastrocytoma in three, and anaplastic oligodendroglioma in two patients).
Twenty-six patients had previously undergone surgical debulking, whereas four patients had only undergone biopsy, as the tumor was either multifocal or in an unfavorable area for resection. All patients had received standard focal radiation therapy with 2-60 Gy/fraction. All patients with GBM (n = 16) had been initially treated according to the actual standard of care with concomitant and adjuvant temozolomide, in addition to six of the 14 patients with grade 3 gliomas. All but one patient had received previous chemotherapy, 18 patients (60%) in median three lines (range 1-6). In second line therapy, dose-dense temozolomide was the agent most often used, followed by imatinib. Sorafenib treatment was initiated at a median of 37.5 (range 4-192) months after the first diagnosis of glioma. This interval was shorter in the subgroup of patients with glioblastoma, with a median of 21 (range 4-168) months.
Efficacy
All 30 patients received sorafenib 400 mg twice daily as a continuous oral schedule.
The median time-to-progression was 3 months [95% confidence interval (CI) 1.9-4.1 months] in GBM patients and 3.1 months (95% CI 1.4-4.8 months) in HGG patients. Seven patients were treated for more than 6 months (23.3% PFS-6) and two of them (6.7%) for more than 1 year. Analyses provided no evidence that patient's age, sex, prior surgery, or radiation therapy was associated with PFS.
Disease progression was the most common reason for discontinuing sorafenib therapy (16 patients, 53.3%), followed by death (seven patients, 23.3%), and one fatal toxicity (3.3%). Three patients were lost to follow-up. Four patients included in the analysis were still being treated with sorafenib at the date of this analysis, one with glioblastoma (9 months on therapy) and three with anaplastic astrocytoma (3.5, 19, and 24.5 months on therapy, respectively).
There was no complete response. The best responses recorded during sorafenib therapy were partial responses in three patients (10%). Twelve patients (40%) achieved stable disease as the best response, whereas half of the patients had progressive disease. The disease control rate, reflecting partial response or stable disease, was 50% for the 30 patients analyzed.
Treatment-related toxicity is detailed in Table 2 . The treatment was well tolerated by 14 patients who reported no or only mild side effects during treatment with sorafenib. Most of the other events were moderate in severity, with hypertension as the most frequent toxicity. In one patient, pre-existent hypertension led to treatment discontinuation. Serious adverse events occurring during treatment were: one patient with hyperglycemia (800 mg/dl) requiring hospitalization and one fatal event -a case of cerebral bleeding in a patient with multifocal GBM who received sorafenib as third line therapy. The bleeding occurred in the 8th month of therapy ( Table 3 ).
The OS was reached in median 6 (95% CI 3.9-8.0) months in GBM patients and in 10 (95% CI 3.1-16.9) months in patients with HGG ( Fig. 1 ).
Discussion
In our retrospective series, sorafenib showed a short period of disease stabilization in most patients with pretreated malignant glioma, which did not exceed 3 months in median for 30 patients. Thus, with all restrictions according to the methodological impossibilities of comparing phase II studies with a retrospective case series, our data did not fulfill expectations that the multikinase inhibitory action of sorafenib would result in more clinical benefit than the targeted therapy with antivascular endothelial growth factor antibody bevacizumab [11] [12] [13] . However, a subgroup of patients had a period of PFS exceeding 6 months, with seven patients (23.3%) surviving progression for at least 6 months. The disease control rate was 50%. These data are in the same range as reported by phase I and II studies using sorafenib alone or in combination with temozolomide, temsirolimus, and erlotinib ( Table 4 ).
The administration of sorafenib in our retrospective series was well tolerated by most patients, with grade 3 and 4 toxicity being uncommon. However, one fatal toxicity occurred in this small group of patients, underlining the risk associated with antiangiogenic therapies in patients with gliomas. To prevent such serious events, we informed patients and their relatives about the potential risk and insisted on continuous monitoring of blood pressure twice daily by the care giver. We stopped the treatment immediately in case of noncompliance. The most Table 3 Adverse events and toxicity   Adverse event  Grade 2  Grade 3  Grade 4  Grade 5   Hypertension  5  2  --Thrombocytopenia  2  ---Skin rash  2  ---Urinary tract infection  -1  --Cerebral bleeding  ---1  Diarrhea  1 Overall survival of 30 patients with recurrent malignant gliomas treated with sorafenib. OS in months after treatment initiation with sorafenib. GBM, glioblastoma multiforme; HGG, high-grade glioma, WHO III; OS, overall survival. Table 4 Sorafenib for patients with recurrent or progressive malignant glioma commonly reported drug-related adverse event was hypertension (23.3%, all grades), a known side effect of sorafenib [23] . The incidence and severity of skin problems was very low (rash and hand-foot skin reaction 10%) as compared with other studies in patients with HGG. For example, in the phase I trial by Nabors et al. [9] , dermatological toxicity affected 17% of the patients enrolled and was the most common adverse event in this study. In the study by Zustovich et al. [16] , the incidence of hand-foot syndrome was 12 of 43 patients with grade 1-2 and four patients with grade 3-4. We think that the low frequency in our series is the consequence of our detailed and insistent instruction to patients on prophylaxis and treatment of any first skin symptoms.
Sorafenib appears as an attractive therapeutic option in HGG because it inhibits several biologically relevant oncogenic pathways and exerts an indirect antitumor effect by blocking angiogenesis. To date, there are only limited data on sorafenib in patients with recurrent or progressive HGG. Moreover, the analysis of only sorafenib in monotherapy reports mainly pharmacokinetics and the MTD, and less commonly efficacy. In fact, at ASCO 2007 Nabors et al. [14] presented a phase I dose-escalation study to the MTD of sorafenib in patients with recurrent malignant glioma. Their conclusion was that sorafenib was well tolerated with limited toxicities up to doses of 800 mg twice daily in patients without concurrent enzymeinducing anticonvulsant drugs (EIAEDs). In the study by Nabors et al. [9] in 2011, the last sentence is as follows: 'In the setting of heavily pretreated patients, sorafenib should be considered for further evaluation given the ease of administration, tolerable side effect profile, and favourable pharmacokinetics at the MTD established by this study'. However, the study lacks efficacy data.
This special interest on pharmacokinetics can also be seen in further studies evaluating sorafenib in combination with other strategies. Reardon et al. [15] investigated the effect of CYP3A-inducing EIAEDs on sorafenib exposure in adults with recurrent glioblastoma receiving sorafenib together with protracted, daily temozolomide.
The study data suggest -in contrast to Nabors et al. [9] that patients on EIAEDs may become significantly underdosed regarding sorafenib compared with patients without EIAEDs. The authors conclude that this could contribute to the 'disappointing outcome' of the evaluated regime consisting of sorafenib and temozolomide with a PFS-6 of only 9.4 and further 15 patients with the best response of stable disease (47%), whereas 16 patients (50%) had already progressed at the first study assessment. Another phase II study investigated the combination of sorafenib and temozolomide in 43 patients with relapsed glioblastoma. In this trial, sorafenib 400 mg twice daily and protracted temozolomide 40 mg/m 2 daily showed 'some activity' [16] . Of the 42 evaluable patients, five patients (12%) achieved a partial response, 18 (43%) had stable disease, and 20 (48%) had progression. The median timeto-progression was 3.2 months.
The North American Brain Tumor Consortium (NABTT) conducted a phase II and pharmacokinetic study on sorafenib and erlotinib [17, 18] . Patients with recurrent or progressive glioblastoma received sorafenib 400 mg twice daily and erlotinib 150 mg once daily until progression. Although PFS at 6 months (14%) compared favorably with historical controls within the NABTT Consortium, the study did not reach its primary endpoint [18] . Pharmacokinetic studies demonstrated a significant and potentially clinically important increase in the clearance of erlotinib by sorafenib that may negatively impact the efficacy of this combination regimen. A further combination of sorafenib and temsirolimus was evaluated in the NCCTG N0572 study in patients with recurrent glioblastoma. In this phase I/II study, the MTD was established for sorafenib at 200 mg twice daily and temsirolimus 20 mg/m 2 weekly [19] . Median time-to-progression reached 1.8 months and median OS reached 5 months. The primary endpoint threshold for success was not met [20] . In a similar trial by the NABTT (05-02), the MTD was 400 mg twice daily for sorafenib combined with 25 mg of temsirolimus weekly. No patient remained progression free at 6 months [21] . The authors discussed two reasons for the disappointing outcome: the first was that the MTD of temsirolimus was only one-tenth of the single agent dose for glioblastoma and the second was the limited central nervous system penetration of sorafenib [22] .
In summary, in this retrospective series, sorafenib monotherapy showed some activity in heavily pretreated patients with recurrent or progressive HGG. The overall rate of serious adverse events was low, and the riskbenefit ratio was acceptable in the context of apparent clinical benefit in patients with a fatal disease. The impact of sorafenib in heavily pretreated patients with HGG may merit further evaluation, given the current limited oral therapeutic options in the setting of recurrence or progression. Future trials should aim to identify the subtypes of HGG responsive to sorafenib.
